Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Pfizer Inc.
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
Today 13:30 EDT
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Declares Second-Quarter 2025 Dividend
April 23, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting
April 23, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease
April 16, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron
April 14, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Shareholders to Attend Virtual 2025 Annual Meeting of Shareholders on April 24
April 10, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
European Commission Approves Pfizer’s RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease
April 01, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of April 29 Conference Call with Analysts
March 18, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
February 24, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
February 13, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
February 12, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
February 10, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance
February 04, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer’s BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial
February 03, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium
January 28, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer’s BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
January 25, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
January 10, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
January 06, 2025
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
December 20, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts
December 19, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance
December 17, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer’s IBRANCE® in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast Cancer
December 12, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of December 17 Conference Call with Analysts to Provide Full-Year 2025 Financial Guidance
December 10, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Showcases Scientific Leadership in Breast Cancer and Blood Disorders Across More than 100 Presentations at ASH and SABCS
December 05, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Announces New Chief Scientific Officer and President, Research & Development
November 20, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
European Commission Approves Pfizer’s HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors
November 20, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
November 14, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
November 04, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance
October 29, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older
October 23, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.